Calmark receives patent number for granted patent in the United States

Calmark Sweden AB (publ) has received announcement from the US Patent Office ("USPTO") regarding a granted patent covering the Calmark POC system and the method of detecting a biomarker in, for example, blood. The patent number is 11255864 and it is valid until April 6, 2039. Advance notice of this was press released on December 8, 2021.

As previously announced, on December 8, 2021, the USPTO issued a so-called Notice of Allowance, which is a preliminary announcement that the patent will be granted. The number of the patent that has been finally granted is hereby announced.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.